RAPT Live signaler | Maksimer profitt med Getagraph.com

SELG 107955 min ago

@ $24.99

Utstedt: 13 feb 2024 @ 21:43

Avkastning: -67.59%

Forrige signal: feb 13 - 15:30

Forrige signal: Kjøp

Avkastning: 0.73 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Stats
Dagens volum	294 633
Gjennomsnittsvolum	1.35M
Markedsverdi	281.86M
EPS	$0 ( 2024-03-12 )
Neste inntjeningsdato	( $-0.780 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.66
ATR14	$0.0110 (0.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Robbins Wendye	Buy	6 925	Stock Option (right to buy)
2024-03-28	Gray Mary Ann	Buy	8 574	Stock Option (right to buy)
2024-03-28	Rieflin William Jl	Buy	11 871	Stock Option (right to buy)
2024-01-31	Ho William	Buy	75 000	Employee Stock Option (right to buy)
2024-01-31	Young Rodney Kb	Buy	90 000	Employee Stock Option (right to buy)

INSIDER POWER
94.05
Last 100 transactions
Buy: 3 742 359 \| Sell: 63 895

Volum Korrelasjon

Lang: -0.07 (neutral)

Kort: -0.76 (moderate negative)

Signal:(31.973) Neutral

Rapt Therapeutics Inc Korrelasjon

10 Mest positive korrelasjoner
RDUS	0.903
ICON	0.901
ATCX	0.9
SYKE	0.898
PAE	0.889
BRACU	0.886
RCON	0.884
CLBT	0.884
ABNB	0.878
DKNG	0.876

10 Mest negative korrelasjoner
VIEW	-0.886
SBBP	-0.863
TUEM	-0.855
LGHL	-0.855
ARDS	-0.848
LCAP	-0.844
RPTX	-0.839
AHPI	-0.839
MTEX	-0.838
NAKD	-0.838

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Rapt Therapeutics Inc Korrelasjon - Valuta/Råvare

-0.58
( weak negative )

-0.62
( weak negative )

0.00
( neutral )

-0.52
( weak negative )

0.00
( neutral )

0.25
( neutral )

Rapt Therapeutics Inc Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-3.55M (0.00 %)
EPS:	$-3.05

FY	2023
Omsetning:	$0
Bruttogevinst:	$-3.55M (0.00 %)
EPS:	$-3.05

FY	2022
Omsetning:	$1.53M
Bruttogevinst:	$-1.28M (-83.82 %)
EPS:	$-2.52

FY	2021
Omsetning:	$3.81M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-2.53

Financial Reports:

No articles found.

Rapt Therapeutics Inc

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.